Catheter Precision Inc.
$ 0.88
-1.58%
17 Apr - close price
- Market Cap 2,369,600 USD
- Current Price $ 0.88
- High / Low $ 0.92 / 0.86
- Stock P/E N/A
- Book Value 2.62
- EPS -15.90
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -1.92 %
- 52 Week High 15.77
- 52 Week Low 0.79
About
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.
Analyst Target Price
$2.00
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2025-11-13 | 2025-08-11 | 2025-05-05 | 2025-03-27 | 2024-11-14 | 2024-08-14 | 2024-05-06 | 2024-03-29 | 2023-12-21 | 2023-08-14 | 2023-06-02 |
| Reported EPS | -3.3227 | -1.7 | -5.93 | -0.3585 | -1.3475 | -38.19 | -105.83 | -68.4 | -2.8 | -0.28 | -11.5 | -24.65 |
| Estimated EPS | None | 0.08 | 0.02 | 0.05 | -0.2 | -3.42 | -4.94 | -7.98 | -2.3 | -0.23 | -3.02 | -0.34 |
| Surprise | 0 | -1.78 | -5.95 | -0.4085 | -1.1475 | -34.77 | -100.89 | -60.42 | -0.5 | -0.05 | -8.48 | -24.31 |
| Surprise Percentage | None% | -2225% | -29750% | -817% | -573.75% | -1016.6667% | -2042.3077% | -757.1429% | -21.7391% | -21.7391% | -280.7947% | -7150% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTAK
2026-04-16 15:39:22
Catheter Precision (VTAK) recently secured shareholder approval for its acquisition of Fly Flyte, integrating Flyte as a fully owned subsidiary to enhance its operations and revenue. This strategic move aims to strengthen VTAK's position in cardiac electrophysiology, despite the company's current low GF Score™ of 36/100, indicating significant financial and profitability challenges. Investors are advised to proceed with caution due to the negative earnings and lack of insider trading activity.
2026-04-16 11:39:22
Catheter Precision (VTAK) has completed the shareholder-approved acquisition of Flyte, making it a wholly-owned subsidiary. This deal immediately consolidates Flyte's revenue, assets, and operations, providing VTAK with direct exposure to cash flow from FAA Part 135 certified regional air services. The acquisition is seen as a transformational step, positioning VTAK for scalable growth in regional air mobility with a revenue-generating aviation platform.
2026-04-16 08:38:53
Catheter Precision, Inc. announced the results of its Special Meeting of Shareholders, where proposals for issuing common stock related to the conversion of various series of preferred stock (C-1, C-2, C-3, C-4, D, and J), and shares from a reduced Series B conversion price, were approved. Shareholders also authorized a reverse stock split at a ratio from 1-for-2 to 1-for-100 and granted flexibility to adjourn future meetings. These approvals provide financial flexibility but also pose potential dilution for existing common shareholders and could impact the company's stock price and market perception.
2026-04-15 23:39:22
Catheter Precision (NYSE:VTAK) stockholders have approved six proposals at a special meeting, including the issuance of common shares for various series of convertible preferred stock and an amendment allowing for a reverse stock split. The company aims to streamline operations and focus on its Flyte aviation platform following a potential divestiture of its cardiac electrophysiology business, despite reporting a significant revenue increase but also a net loss in 2025.
2026-04-15 21:10:05
Catheter Precision, Inc. stockholders approved six proposals at a special meeting, including the issuance of common shares for various convertible preferred stocks and an amendment allowing for a reverse stock split. These approvals come as the company, with a market capitalization of $2.83 million, trades at $1.03 per share, down 82% over the past year. The company recently reported a significant revenue increase in 2025 but also a net loss, and is exploring the sale of its cardiac electrophysiology business to focus on its Flyte aviation platform.
2026-04-15 20:10:05
Catheter Precision, Inc. (NYSE: VTAK) held a Special Meeting on April 15, 2026, where 49.5% of its outstanding shares were represented. Stockholders voted on six proposals detailed in the company's proxy statement, all of which passed. The event was classified as Item 5.07 – Submission of Matters to a Vote of Security Holders in its 8-K filing.
